Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NCKIPSD
REST API REST API
Homo sapiens
NCKIPSD is differentially expressed in 223 experiments: 113 organism parts: bone marrow, amygdala, ... (111 more);, 157 disease states: normal, Emery-Dreifuss muscular dystrophy, ... (155 more);, 76 cell types 250 cell lines 26 compound treatments and 59 other conditions.
Synonyms ORF1, DIP1, SPIN90, AF3P21, WISH, WASLBP
Orthologs ENSCING00000002255 (Ciona intestinalis)   Nckipsd (Rattus norvegicus)   ENSCING00000016244 (Ciona intestinalis)   NCKIPSD (Gallus gallus)   Nckipsd (Mus musculus)   NCKIPSD (Bos taurus)   NCKIPSD (Danio rerio)   CG2258 (Drosophila melanogaster)   nckipsd (Xenopus laevis)   NCKIPSD (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoskeleton organization, protein binding, SH3 domain binding, NLS-bearing substrate import into nucleus, nucleus, signalosome, cytoskeletal protein binding, intermediate filament, signal transduction
InterPro Term SH3_domain, SH3_2, DUF2013
UniProt Accession Q9NZQ3, C9JC20, C9JMQ4, C9JSC3, F8WCR8
Search EB-eye ENSG00000213672
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-GEOD-1577, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639, E-GEOD-5823
SNU5
2
E-MTAB-37, E-GEOD-15460
U87
2
E-MEXP-903, E-GEOD-20089
PC3
2
E-MEXP-2034, E-GEOD-5258
AsPC1
1
E-MTAB-37
SW780
1
E-MTAB-37
244 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
mononuclear
2
E-GEOD-13987, E-GEOD-26672
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
ovarian cancer
1
E-GEOD-21154
secretory cell
1
E-GEOD-3998
hematopoietic
1
E-GEOD-9894
70 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, ... (44 experiments)

Factor Value U/D Experiments
myeloma
2
E-MTAB-372, E-MTAB-37
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
juvenile dermatomyositis
2
E-GEOD-3307, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
151 more value(s).


Compound treatment

studied in E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (15 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-MEXP-1958, E-TABM-868, E-GEOD-20719, E-MEXP-1601, ... (7 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
resveratrol
1
E-TABM-782
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
N-nitrosodimethylamine
1
E-GEOD-6907
actinomycin D
1
E-GEOD-6400
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-20499

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-20847

Genotype
studied in E-GEOD-17476, E-MEXP-1235, E-TABM-868, E-TABM-601, E-GEOD-17347, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-20504, E-GEOD-9764, E-GEOD-10315, ... (7 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-2069, E-TABM-666, ... (22 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1309, E-GEOD-17636, E-GEOD-2487, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Processing time: 0.507 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM